Adma Biologics Inc Earnings

Adma Biologics Inc’s revenue jumped 78.13% since last year same period to $119.84Mn in the Q3 2024. On a quarterly growth basis, Adma Biologics Inc has generated 11.8% jump in its revenue since last 3-months.

Adma Biologics Inc’s net profit jumped 1299.93% since last year same period to $35.91Mn in the Q3 2024. On a quarterly growth basis, Adma Biologics Inc has generated 12% jump in its net profits since last 3-months.

Adma Biologics Inc’s net profit margin jumped 685.89% since last year same period to 29.96% in the Q3 2024. On a quarterly growth basis, Adma Biologics Inc has generated 0.18% jump in its net profit margins since last 3-months.

Adma Biologics Inc’s price-to-earnings ratio after this Q3 2024 earnings stands at 64.44.

Adma Biologics Inc’s earning per share (EPS) estimates for the current quarter stand at 0.14 - a 11.54% jump from last quarter’s estimates.

Adma Biologics Inc’s earning per share (EPS) estimates for the current year stand at 0.14.

Adma Biologics Inc’s earning per share (EPS) jumped 1400% since last year same period to 0.15 in the Q3 2024. This indicates that the Adma Biologics Inc has generated 1400% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Adma Biologics Inc’s return on assets (ROA) stands at 0.2.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Adma Biologics Inc’s return on equity (ROE) stands at 0.36.